Chemotherapy-Induced Neutropenia/Febrile Neutropenia Prophylaxis with Biosimilar Filgrastim in Solid Tumors Versus Hematological Malignancies: MONITOR-GCSF Study

References

• Lalami Y , PaesmansM, MuanzaFet al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann. Oncol.17, 507–514 (2006).
   PubMed Web of Science ®Google Scholar
• Lalami Y , PaesmansM, AounMet al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer12, 725–730 (2004).
   PubMed Web of Science ®Google Scholar
• Lyman GH , LymanCH, AgboolaO. Risk models for predicting chemotherapy-induced neutropenia. Oncologist10, 427–437 (2005).
   PubMed Web of Science ®Google Scholar
• Lyman GH , DaleDC, CulakovaEet al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann. Oncol.24, 2475–2484 (2013).
   PubMed Web of Science ®Google Scholar
• Lyman GH , AbellaE, PettengellR. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit. Rev. Oncol. Hematol.90, 190–199 (2014).
   PubMed Web of Science ®Google Scholar
• Aapro MS , BohliusJ, CameronDAet al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer47, 8–32 (2011).
   PubMed Web of Science ®Google Scholar
• Smith TJ , BohlkeK, LymanGHet al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol.33, 3199–3212 (2015).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Myeloid growth factors. Version 2 (2018). www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.
   Google Scholar
• Wingard JR , ElmongyM. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit. Rev. Oncol. Hematol.72, 144–154 (2009).
   PubMed Web of Science ®Google Scholar
• Gridelli C , AaproM, BarniSet al. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit. Rev. Oncol. Hematol.63, 53–64 (2007).
   PubMed Web of Science ®Google Scholar
• Klastersky J , AwadaA. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice?Crit. Rev. Oncol. Hematol.78, 17–23 (2011).
   PubMed Web of Science ®Google Scholar
• Klastersky J , AwadaA, PaesmansM, AounM. Febrile neutropenia: a critical review of the initial management. Crit. Rev. Oncol. Hematol.78, 185–194 (2011).
   PubMed Web of Science ®Google Scholar
• Cooper KL , MadanJ, WhyteS, StevensonMD, AkehurstRL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer11, 404 (2011).
   PubMed Web of Science ®Google Scholar
• Lyman G , DaleD, WolffDAet al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol.28, 2914–2924 (2010).
   PubMed Web of Science ®Google Scholar
• Giebel S , ThomasX, HallbookHet al. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur. J. Cancer48, 360–367 (2012).
   PubMed Web of Science ®Google Scholar
• Wheatley K , GoldstoneAH, LittlewoodT, HunterA, BurnettAK. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br. J. Haematol.146, 54–63 (2009).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes. Version 2 (2018). www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
   Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Acute myeloid leukemia. Version 2 (2018). www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
   Google Scholar
• Gascón P , AaproM, LudwigHet al. Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit. Rev. Oncol. Hematol.77, 184–197 (2011).
   PubMed Web of Science ®Google Scholar
• Gascón P , AaproM, LudwigHet al. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: protocol amendments. Crit. Rev. Oncol. Hematol.77, 198–200 (2011).
   PubMed Web of Science ®Google Scholar
• Gascón P , AaproM, LudwigHet al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer24, 911–925 (2016).
   PubMed Web of Science ®Google Scholar
• Aapro M , LudwigH, BokemeyerPet al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann. Oncol.27, 2039–2045 (2016).
   PubMed Web of Science ®Google Scholar
• Twisk JWR . Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide (2nd Edition). Cambridge University Press, Cambridge, UK (2013).
   Google Scholar